α1-Antitrypsin combines with plasma fatty acids and induces angiopoietin-like protein 4 expression

Journal of Immunology

Volumn 195, Issue 8, 2015, Pages 3605-3616

  Frenzel, Eileen ^a,b   Wrenger, Sabine ^a,b   Brügger, Britta ^c   Salipalli, Sandeep ^a,b   Immenschuh, Stephan ^a   Aggarwal, Nupur ^a,b   Lichtinghagen, Ralf ^a   Mahadeva, Ravi ^d   Marcondes, A Mario Q ^e,f   Dinarello, Charles A ^g,h   Welte, Tobias ^a,b   Janciauskiene, Sabina ^a,b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Member of the German Center for Lung Research   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f USA   (United States)

^g UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^h RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA 1 ANTITRYPSIN CONCENTRATE; ANGIOPOIETIN; ANGIOPOIETIN LIKE PROTEIN 4; CD14 ANTIGEN; CD36 ANTIGEN; FATTY ACID; FATTY ACID BINDING PROTEIN 4; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; UNCLASSIFIED DRUG; ANGPTL4 PROTEIN, HUMAN; FABP4 PROTEIN, HUMAN; FATTY ACID BINDING PROTEIN; LINOLEIC ACID; OLEIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

AFFINITY CHROMATOGRAPHY; ANGPTL4 GENE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FABP4 GENE; GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOREGULATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LIPID INTERACTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; UPREGULATION; WESTERN BLOTTING; BIOSYNTHESIS; BLOOD; FEMALE; IMMUNOLOGY; MALE; METABOLISM; MONOCYTE;

ALPHA 1-ANTITRYPSIN; ANGIOPOIETINS; FATTY ACID-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LINOLEIC ACID; MALE; MONOCYTES; OLEIC ACID; PPAR GAMMA;

EID: 84943539033     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1500740     Document Type: Article

References (72)

1. Yoon, J. C., T. W. Chickering, E. D. Rosen, B. Dussault, Y. Qin, A. Soukas, J. M. Friedman, W. E. Holmes, and B. M. Spiegelman. 2000. Peroxisome proliferator-activated receptor gamma target gene encoding a novel angiopoietinrelated protein associated with adipose differentiation. Mol. Cell. Biol. 20:5343-5349.
2. Yoshida, K., T. Shimizugawa, M. Ono, and H. Furukawa. 2002. Angiopoietinlike protein 4 is a potent hyperlipidemia-inducing factor in mice and inhibitor of lipoprotein lipase. J. Lipid Res. 43:1770-1772.
3. Sukonina, V., A. Lookene, T. Olivecrona, and G. Olivecrona. 2006. Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue. Proc. Natl. Acad. Sci. USA 103:17450-17455.
4. Lichtenstein, L., F. Mattijssen, N. J. de Wit, A. Georgiadi, G. J. Hooiveld, R. van der Meer, Y. He, L. Qi, A. Köster, J. T. Tamsma, et al. 2010. Angptl4 protects against severe proinflammatory effects of saturated fat by inhibiting fatty acid uptake into mesenteric lymph node macrophages. Cell Metab. 12:580-592.
5. Georgiadi, A., Y. Wang, R. Stienstra, N. Tjeerdema, A. Janssen, A. Stalenhoef, J. A. van der Vliet, A. de Roos, J. T. Tamsma, J. W. Smit, et al. 2013. Overexpression of angiopoietin-like protein 4 protects against atherosclerosis development. Arterioscler. Thromb. Vasc. Biol. 33:1529-1537.
6. Adachi, H., Y. Fujiwara, T. Kondo, T. Nishikawa, R. Ogawa, T. Matsumura, N. Ishii, R. Nagai, K. Miyata, M. Tabata, et al. 2009. Angptl 4 deficiency improves lipid metabolism, suppresses foam cell formation and protects against atherosclerosis. Biochem. Biophys. Res. Commun. 379:806-811.
7. Goh, Y. Y., M. Pal, H. C. Chong, P. Zhu, M. J. Tan, L. Punugu, C. K. Tan, R. L. Huang, S. K. Sze, M. B. Tang, et al. 2010. Angiopoietin-like 4 interacts with matrix proteins to modulate wound healing. J. Biol. Chem. 285:32999-33009.
8. Galaup, A., A. Cazes, S. Le Jan, J. Philippe, E. Connault, E. Le Coz, H. Mekid, L. M. Mir, P. Opolon, P. Corvol, et al. 2006. Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness. Proc. Natl. Acad. Sci. USA 103:18721-18726.
9. Clement, L. C., C. Avila-Casado, C. Macé, E. Soria, W. W. Bakker, S. Kersten, and S. S. Chugh. 2011. Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome. Nat. Med. 17:117-122.
10. Galaup, A., E. Gomez, R. Souktani, M. Durand, A. Cazes, C. Monnot, J. Teillon, S. Le Jan, C. Bouleti, G. Briois, et al. 2012. Protection against myocardial infarction and no-reflow through preservation of vascular integrity by angiopoietin-like 4. Circulation 125:140-149.
11. Xu, A., M. C. Lam, K. W. Chan, Y. Wang, J. Zhang, R. L. Hoo, J. Y. Xu, B. Chen, W. S. Chow, A. W. Tso, and K. S. Lam. 2005. Angiopoietin-like protein 4 decreases blood glucose and improves glucose tolerance but induces hyperlipidemia and hepatic steatosis in mice. Proc. Natl. Acad. Sci. USA 102:6086-6091.
12. Mehta, N., A. Qamar, L. Qu, A. N. Qasim, N. N. Mehta, M. P. Reilly, and D. J. Rader. 2014. Differential association of plasma angiopoietin-like proteins 3 and 4 with lipid and metabolic traits. Arterioscler. Thromb. Vasc. Biol. 34:1057-1063.
13. Ruge, T., V. Sukonina, O. Kroupa, E. Makoveichuk, M. Lundgren, M. K. Svensson, G. Olivecrona, and J. W. Eriksson. 2012. Effects of hyperinsulinemia on lipoprotein lipase, angiopoietin-like protein 4, and glycosylphosphatidylinositol-anchored high-density lipoprotein binding protein 1 in subjects with and without type 2 diabetes mellitus. Metabolism 61:652-660.
14. Georgiadi, A., L. Lichtenstein, T. Degenhardt, M. V. Boekschoten, M. van Bilsen, B. Desvergne, M. Müller, and S. Kersten. 2010. Induction of cardiac Angptl4 by dietary fatty acids is mediated by peroxisome proliferator-activated receptor beta/delta and protects against fatty acid-induced oxidative stress. Circ. Res. 106:1712-1721.
15. Kersten, S., L. Lichtenstein, E. Steenbergen, K. Mudde, H. F. Hendriks, M. K. Hesselink, P. Schrauwen, and M. Müller. 2009. Caloric restriction and exercise increase plasma ANGPTL4 levels in humans via elevated free fatty acids. Arterioscler. Thromb. Vasc. Biol. 29:969-974.
16. Catoire, M., S. Alex, N. Paraskevopulos, F. Mattijssen, I. Evers-van Gogh, G. Schaart, J. Jeppesen, A. Kneppers, M. Mensink, P. J. Voshol, et al. 2014. Fatty acid-inducible ANGPTL4 governs lipid metabolic response to exercise. Proc. Natl. Acad. Sci. USA 111:E1043-E1052.
17. Spector, A. A. 1975. Fatty acid binding to plasma albumin. J. Lipid Res. 16:165-179.
18. Fujiwara, S., and T. Amisaki. 2006. Molecular dynamics study of conformational changes in human serum albumin by binding of fatty acids. Proteins 64:730-739.
19. van der Vusse, G. J. 2009. Albumin as fatty acid transporter. Drug Metab. Pharmacokinet. 24:300-307.
20. Sabina, J., and W. Tobias. 2013. Augmentation therapy with alpha1-antitrypsin: novel perspectives. Cardiovasc. Hematol. Disord. Drug Targets 13:90-98.
21. Stockley, R. A. 2014. Alpha1-antitrypsin review. Clin. Chest Med. 35:39-50.
22. 1-Antitrypsin therapy downregulates Tolllike receptor-induced IL-1β responses in monocytes and myeloid dendritic cells and may improve islet function in recently diagnosed patients with type 1 diabetes. J. Clin. Endocrinol. Metab. 99:E1418-E1426.
23. Abbate, A., B. W. Van Tassell, S. Christopher, N. A. Abouzaki, C. Sonnino, C. Oddi, S. Carbone, R. D. Melchior, M. L. Gambill, C. S. Roberts, et al. 2015. Effects of prolastin C (plasma-derived alpha-1 antitrypsin) on the acute inflammatory response in patients with ST-segment elevation myocardial infarction (from the VCU-alpha 1-RT pilot study). Am. J. Cardiol. 115:8-12.
24. 1-antitrypsin-a novel regulator of angiopoietin-like protein 4 transcription and secretion. J. Immunol. 192:5354-5362.
25. Özbalci, C., T. Sachsenheimer, and B. Brügger. 2013. Quantitative analysis of cellular lipids by nano-electrospray ionization mass spectrometry. Methods Mol. Biol. 1033:3-20.
26. Beck-García, E., K. Beck-García, A. Schlosser, and W. W. Schamel. 2013. Analysis of interactions between proteins and fatty acids or cholesterol using a fatty acid/cholesterol pull-down assay. Anal. Biochem. 436:75-77.
27. Dorresteijn, M. J., A. Paine, E. Zilian, M. G. Fenten, E. Frenzel, S. Janciauskiene, C. Figueiredo, B. Eiz-Vesper, R. Blasczyk, D. Dekker, et al. 2015. Cell-type-specific downregulation of heme oxygenase-1 by lipopolysaccharide via Bach1 in primary human mononuclear cells. Free Radic. Biol. Med. 78:224-232.
28. Janciauskiene, S. M., I. M. Nita, and T. Stevens. 2007. Alpha1-antitrypsin, old dog, new tricks: alpha1-antitrypsin exerts in vitro anti-inflammatory activity in human monocytes by elevating cAMP. J. Biol. Chem. 282:8573-8582.
29. Nukiwa, T., M. Brantly, F. Ogushi, G. Fells, K. Satoh, L. Stier, M. Courtney, and R. G. Crystal. 1987. Characterization of the M1 (Ala213) type of alpha 1-antitrypsin, a newly recognized, common "normal" alpha 1-antitrypsin haplotype. Biochemistry 26:5259-5267.
30. Agardh, H. E., L. Folkersen, J. Ekstrand, D. Marcus, J. Swedenborg, U. Hedin, A. Gabrielsen, and G. Paulsson-Berne. 2011. Expression of fatty acid-binding protein 4/aP2 is correlated with plaque instability in carotid atherosclerosis. J. Intern. Med. 269:200-210.
31. Bonen, A., S. E. Campbell, C. R. Benton, A. Chabowski, S. L. Coort, X. X. Han, D. P. Koonen, J. F. Glatz, and J. J. Luiken. 2004. Regulation of fatty acid transport by fatty acid translocase/CD36. Proc. Nutr. Soc. 63:245-249.
32. Kaddatz, K., T. Adhikary, F. Finkernagel, W. Meissner, S. Müller-Brüsselbach, and R. Müller. 2010. Transcriptional profiling identifies functional interactions of TGF β and PPAR β/δ signaling: synergistic induction of ANGPTL4 transcription. J. Biol. Chem. 285:29469-29479.
33. Lichtenstein, L., and S. Kersten. 2010. Modulation of plasma TG lipolysis by angiopoietin-like proteins and GPIHBP1. Biochim. Biophys. Acta 1801:415-420.
34. Chana, R. S., A. J. Lewington, and N. J. Brunskill. 2004. Differential effects of peroxisome proliferator activated receptor-gamma (PPAR gamma) ligands in proximal tubular cells: thiazolidinediones are partial PPAR gamma agonists. Kidney Int. 65:2081-2090.
35. Parr, D. G., D. G. Stewart, I. Hero, and R. A. Stockley. 2003. Panniculitis secondary to extravasation of clarithromycin in a patient with alpha 1-antitrypsin deficiency (phenotype PiZ). Br. J. Dermatol. 149:410-413.
36. Cowden, D. I., G. E. Fisher, and R. L. Weeks. 2005. A pilot study comparing the purity, functionality and isoform composition of alpha-1-proteinase inhibitor (human) products. Curr. Med. Res. Opin. 21:877-883.
37. Sanderson, L. M., T. Degenhardt, A. Koppen, E. Kalkhoven, B. Desvergne, M. Müller, and S. Kersten. 2009. Peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) but not PPARalpha serves as a plasma free fatty acid sensor in liver. Mol. Cell. Biol. 29:6257-6267.
38. Mandard, S., F. Zandbergen, E. van Straten, W. Wahli, F. Kuipers, M. Müller, and S. Kersten. 2006. The fasting-induced adipose factor/angiopoietin-like protein 4 is physically associated with lipoproteins and governs plasma lipid levels and adiposity. J. Biol. Chem. 281:934-944.
39. Robciuc, M. R., E. Tahvanainen, M. Jauhiainen, and C. Ehnholm. 2010. Quantitation of serum angiopoietin-like proteins 3 and 4 in a Finnish population sample. J. Lipid Res. 51:824-831.
40. Jonker, J. T., J. W. Smit, S. Hammer, M. Snel, R. W. van der Meer, H. J. Lamb, F. Mattijssen, K. Mudde, I. M. Jazet, O. M. Dekkers, et al. 2013. Dietary modulation of plasma angiopoietin-like protein 4 concentrations in healthy volunteers and in patients with type 2 diabetes. Am. J. Clin. Nutr. 97:255-260.
41. Wang, J., X. Zhu, Z. Wang, J. Yao, B. Zhao, and G. Liu. 2015. Non-esterified fatty acids promote expression and secretion of angiopoietin-like protein 4 in calf hepatocytes cultured in vitro. Mol. Cell. Biochem. 401:141-146.
42. Staiger, H., C. Haas, J. Machann, R. Werner, M. Weisser, F. Schick, F. Machicao, N. Stefan, A. Fritsche, and H. U. Häring. 2009. Muscle-derived angiopoietin-like protein 4 is induced by fatty acids via peroxisome proliferator-activated receptor (PPAR)-delta and is of metabolic relevance in humans. Diabetes 58:579-589.
43. Alex, S., K. Lange, T. Amolo, J. S. Grinstead, A. K. Haakonsson, E. Szalowska, A. Koppen, K. Mudde, D. Haenen, S. Al-Lahham, et al. 2013. Short-chain fatty acids stimulate angiopoietin-like 4 synthesis in human colon adenocarcinoma cells by activating peroxisome proliferator-activated receptor g. Mol. Cell. Biol. 33:1303-1316.
44. Varga, T., Z. Czimmerer, and L. Nagy. 2011. PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation. Biochim. Biophys. Acta 1812:1007-1022.
45. Gardner, C. D., S. P. Fortmann, and R. M. Krauss. 1996. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 276:875-881.
46. Richieri, G. V. A. M. K., and A. M. Kleinfeld. 1995. Unbound free fatty acid levels in human serum. J. Lipid Res. 36:229-240.
47. Brunaldi, K., N. Huang, and J. A. Hamilton. 2010. Fatty acids are rapidly delivered to and extracted from membranes by methyl-beta-cyclodextrin. J. Lipid Res. 51:120-131.
48. 1-antitrypsin revealed by theory and experiment. Biophys. J. 102:2856-2865.
49. Cabrita, L. D. S. P. B., and S. P. Bottomley. 2004. How do proteins avoid becoming too stable? Biophysical studies into metastable proteins. Eur. Biophys. J. 33:83-88.
50. Inoue, T., T. Kohro, T. Tanaka, Y. Kanki, G. Li, H. M. Poh, I. Mimura, M. Kobayashi, A. Taguchi, T. Maejima, et al. 2014. Cross-enhancement of ANGPTL4 transcription by HIF1 alpha and PPAR beta/delta is the result of the conformational proximity of two response elements. Genome Biol. 15:R63.
51. Savage, D. B., C. P. Sewter, E. S. Klenk, D. G. Segal, A. Vidal-Puig, R. V. Considine, and S. O'Rahilly. 2001. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 50:2199-2202.
52. Seargent, J. M., E. A. Yates, and J. H. Gill. 2004. GW9662, a potent antagonist of PPARgamma, inhibits growth of breast tumor cells and promotes the anticancer effects of the PPARgamma agonist rosiglitazone, independently of PPARgamma activation. Br. J. Pharmacol. 143:933-937.
53. Koliwad, S. K., T. Kuo, L. E. Shipp, N. E. Gray, F. Backhed, A. Y. So, R. V. Farese, Jr., and J. C. Wang. 2009. Angiopoietin-like 4 (ANGPTL4, fastinginduced adipose factor) is a direct glucocorticoid receptor target and participates in glucocorticoid-regulated triglyceride metabolism. J. Biol. Chem. 284:25593-25601.
54. Krey, G., O. Braissant, F. L'Horset, E. Kalkhoven, M. Perroud, M. G. Parker, and W. Wahli. 1997. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol. Endocrinol. 11:779-791.
55. Naruhn, S., P. M. Toth, T. Adhikary, K. Kaddatz, V. Pape, S. Dörr, G. Klebe, S. Müller-Brüsselbach, W. E. Diederich, and R. Müller. 2011. High-affinity peroxisome proliferator-activated receptor b/d-specific ligands with pure antagonistic or inverse agonistic properties. Mol. Pharmacol. 80:828-838.
56. Stapleton, C. M., J. H. Joo, Y. S. Kim, G. Liao, R. A. Panettieri, Jr., and A. M. Jetten. 2010. Induction of ANGPTL4 expression in human airway smooth muscle cells by PMA through activation of PKC and MAPK pathways. Exp. Cell Res. 316:507-516.
57. Prusty, D., B. H. Park, K. E. Davis, and S. R. Farmer. 2002. Activation of MEK/ERK signaling promotes adipogenesis by enhancing peroxisome proliferatoractivated receptor gamma (PPARgamma) and C/EBPalpha gene expression during the differentiation of 3T3-L1 preadipocytes. J. Biol. Chem. 277:46226-46232.
58. Subramaniyam, D., H. Zhou, M. Liang, T. Welte, R. Mahadeva, and S. Janciauskiene. 2010. Cholesterol rich lipid raft microdomains are gateway for acute phase protein, SERPINA1. Int. J. Biochem. Cell Biol. 42:1562-1570.
59. Bergin, D. A., E. P. Reeves, P. Meleady, M. Henry, O. J. McElvaney, T. P. Carroll, C. Condron, S. H. Chotirmall, M. Clynes, S. J. O'Neill, and N. G. McElvaney. 2010. α-1 Antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8. J. Clin. Invest. 120:4236-4250.
60. Vaisar, T., S. Pennathur, P. S. Green, S. A. Gharib, A. N. Hoofnagle, M. C. Cheung, J. Byun, S. Vuletic, S. Kassim, P. Singh, et al. 2007. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J. Clin. Invest. 117:746-756.
61. Talmud, P. J., S. Martin, G. Steiner, D. M. Flavell, D. B. Whitehouse, S. Nagl, R. Jackson, M. R. Taskinen, M. H. Frick, M. S. Nieminen, et al; Diabetes Atherosclerosis Intervention Study Investigators. 2003. Progression of atherosclerosis is associated with variation in the alpha1-antitrypsin gene. Arterioscler. Thromb. Vasc. Biol. 23:644-649.
62. 1-antitrypsin therapy in elastaseinduced pulmonary emphysema. Am. J. Respir. Cell Mol. Biol. 51:536-549.
63. Augsten, M., H. Hackl, B. Ebner, A. Chemelli, O. Glatter, G. Marsche, U. Lang, G. Desoye, and C. Wadsack. 2011. Fetal HDL/apoE: a novel regulator of gene expression in human placental endothelial cells. Physiol. Genomics 43:1255-1262.
64. Stremmel, W., L. Pohl, A. Ring, and T. Herrmann. 2001. A new concept of cellular uptake and intracellular trafficking of long-chain fatty acids. Lipids 36:981-989.
65. 1-antitrypsin without inhibition of elastase. Proc. Natl. Acad. Sci. USA 110:15007-15012.
66. Lewis, E. C. 2012. Expanding the clinical indications for a (1)-antitrypsin therapy. Mol. Med. 18:957-970.
67. Lomas, D. A. R. W. C., and R. W. Carrell. 2002. Serpinopathies and the conformational dementias. Nat. Rev. Genet. 3:759-768.
68. Furuhashi, M., and G. S. Hotamisligil. 2008. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat. Rev. Drug Discov. 7:489-503.
69. Makowski, L., and G. S. Hotamisligil. 2005. The role of fatty acid binding proteins in metabolic syndrome and atherosclerosis. Curr. Opin. Lipidol. 16:543-548.
70. Makowski, L., J. B. Boord, K. Maeda, V. R. Babaev, K. T. Uysal, M. A. Morgan, R. A. Parker, J. Suttles, S. Fazio, G. S. Hotamisligil, and M. F. Linton. 2001. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat. Med. 7:699-705.
71. Makowski, L., K. C. Brittingham, J. M. Reynolds, J. Suttles, and G. S. Hotamisligil. 2005. The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity: macrophage expression of aP2 impacts peroxisome proliferator-activated receptor gamma and IkappaB kinase activities. J. Biol. Chem. 280:12888-12895.
72. Shum, B. O., C. R. Mackay, C. Z. Gorgun, M. J. Frost, R. K. Kumar, G. S. Hotamisligil, and M. S. Rolph. 2006. The adipocyte fatty acid-binding protein aP2 is required in allergic airway inflammation. J. Clin. Invest. 116:2183-2192.